

PFIZER INC  
Form 425  
November 23, 2015

Pfizer and Allergan to Combine  
Creating a New Global Biopharmaceutical  
Leader  
November 2015  
Filing pursuant to Rule 425 under the  
Securities Act of 1933, as amended

Edgar Filing: PFIZER INC - Form 425

Deemed filed under Rule 14a-12 under the  
Securities Exchange Act of 1934, as amended  
Filer: Allergan  
plc  
Subject Company: Pfizer Inc.  
Commission File Number: 001-03619  
Date: November 23, 2015

Information Related to This Communication

2

**NO OFFER OR SOLICITATION**

This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale or transfer of securities in any jurisdiction in contravention of applicable law.

This communication is not intended to be and is not a prospectus for the purposes of Part 23 of the Companies Act 2014 of Ireland.

Act ), Prospectus (Directive 2003/71/EC) Regulations 2005 (S.I. No. 324 of 2005) of Ireland (as amended from time to time) Rules issued by the Central Bank of Ireland pursuant to section 1363 of the 2014 Act, and the Central Bank of Ireland ( CBI ) this communication.

**IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC**

In connection with the proposed transaction between Pfizer Inc. ( Pfizer ) and Allergan plc ( Allergan ), Allergan will file with the Securities and Exchange Commission (the SEC ) a registration statement on Form S-4 that will include a Joint Proxy Statement of Pfizer and Allergan (the Joint Proxy Statement/Prospectus ). Pfizer and Allergan plan to mail to their respective shareholders the definitive Joint Proxy Statement/Prospectus in connection with the transaction. INVESTORS AND SECURITY HOLDERS OF PFIZER AND ALLERGAN ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT PFIZER, ALLERGAN, THE TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the Joint Proxy Statement/Prospectus (when available) and other documents filed with the SEC by Pfizer through the website maintained by the SEC at [www.sec.gov](http://www.sec.gov). In addition, investors and security holders will be able to obtain free copies of documents filed with the SEC by Pfizer by contacting Pfizer Investor Relations at [Bryan.Dunn@pfizer.com](mailto:Bryan.Dunn@pfizer.com) or by calling (212) 261-7488. Investors and security holders will be able to obtain free copies of the documents filed with the SEC by Allergan by contacting Allergan Investor Relations at [investor.relations@actavis.com](mailto:investor.relations@actavis.com) or by calling (862) 261-7488.

**PARTICIPANTS IN THE SOLICITATION**

Pfizer, Allergan and certain of their respective directors, executive officers and employees may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information regarding the persons who may, under the rules of the SEC, be considered participants in the solicitation of the respective shareholders of Pfizer and Allergan in connection with the proposed transaction, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the Joint Proxy Statement/Prospectus filed with the SEC. Information regarding Pfizer's directors and executive officers is contained in Pfizer's proxy statement for its 2015 annual meeting of stockholders, which was filed with the SEC on March 12, 2015, and certain of Pfizer's Current Reports on Form 8-K regarding Allergan's directors and executive officers is contained in Allergan's proxy statement for its 2015 annual meeting of stockholders, which was filed with the SEC on April 24, 2015, and certain of Allergan's Current Reports on Form 8-K.

Forward-Looking Statements

3

Pfizer Cautionary Statement Regarding Forward-Looking Statements

This communication contains certain forward-looking statements with respect to the proposed transaction between Pfizer and A forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-look use future dates or words such as anticipate , target , possible , potential , predict , project , forecast , outlook estimate , intend , plan , goal , believe , hope , aim , continue , will , may , might , would , could

expressions of similar meaning or the negative thereof. Such forward-looking statements include, but are not limited to, statements of the expected benefits of the proposed transaction, including anticipated future financial and operating results, synergies, accretion and growth, Allergan's and the combined company's plans, objectives, expectations, intentions and anticipated financial results, plans related to share repurchases and dividends, and the expected timing of completion of the transaction. There are several factors which could cause actual results and results to differ materially from those expressed or implied in forward-looking statements. Such factors include, but are not limited to, failure to obtain necessary regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could materially affect the combined company or the expected benefits of the transaction) and shareholder approvals or to satisfy any of the other conditions for the transaction on a timely basis or at all, the occurrence of events that may give rise to a right of one or both of the parties to terminate the transaction agreement, adverse effects on the market price of Pfizer's common stock and on Pfizer's operating results because of a failure to complete the transaction in the anticipated time frame or at all, failure to realize the expected benefits and synergies of the transaction, restructuring costs in connection with the transaction and subsequent integration of Pfizer and Allergan, negative effects of the announcement or the completion of the transaction on the market price of Pfizer's common stock and on Pfizer's operating results, risks relating to the value of the securities to be issued in the transaction, significant transaction costs and/or unknown liabilities, the risk of litigation and/or regulatory action, the loss of senior management or scientific staff, general economic and business conditions that affect the companies following the transaction, changes in global, political, economic, business, competitive, market and regulatory forces, future exchange and interest rates, changes in tax laws, regulations, rates and policies, future business combinations or disposals, competitive developments, and the uncertainties inherent in business and development. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they are based on assumptions and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in this communication could cause Pfizer's plans with respect to Allergan, actual results, performance or achievements, industry results and market conditions to differ materially from those expressed in or implied by such forward-looking statements. Persons reading this communication are cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this communication. Pfizer has no obligation to update or revise the information contained in this communication (whether as a result of new information, future developments or otherwise), except as required by applicable law. A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its subsequent reports on Form 10-Q, including in the sections thereof entitled "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 10-Q which are filed with the SEC and available at [www.sec.gov](http://www.sec.gov) and [www.pfizer.com](http://www.pfizer.com).

Forward-Looking Statements

4

Allergan Cautionary Statement Regarding Forward-Looking Statements

Statements contained in this communication that refer to Allergan's anticipated future events, estimated or anticipated future results, or other information that is not based on historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as such as anticipate, target, expect, predict, project, forecast, outlook, guidance, expect, estimate, intend, plan, goal, believe, hope, or similar words.

might, would, could or should or other similar words, phrases or expressions or the negatives thereof. Such forward-looking statements include, but are not limited to, statements about the benefits of the proposed transaction, including future financial and operating synergies, Pfizer's, Allergan's and the combined company's plans, objectives, expectations and intentions, and the expected results of the transaction. It is important to note that Allergan's goals and expectations are not predictions of actual performance. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business, Pfizer's business and the combined company associated with business combination transactions. These factors include, among others, the inherent uncertainty associated with business combination projections; restructuring in connection with, and successful closing of, the proposed transaction; subsequent integration of Pfizer and Allergan and the ability to recognize the anticipated synergies and benefits of the proposed transaction; the ability to obtain required regulatory approvals for the transaction (including the approval of antitrust authorities necessary to complete the transaction), the timing of obtaining such approvals and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company's ability to realize the benefits of the transaction; the ability to obtain the requisite Pfizer and Allergan shareholder approvals; the risk that a condition to the proposed transaction may not be satisfied on a timely basis or at all; the failure of the proposed transaction to close for any other reason; fluctuations relating to the value of the Allergan shares to be issued in the transaction; the anticipated size of the markets and continued demand for Pfizer and Allergan's products; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of regulatory actions on pricing; market acceptance of and continued demand for Allergan's and Pfizer's products; difficulties or delays in manufacturing; fluctuations in foreign currency exchange rates; the risks and uncertainties normally incident to the pharmaceutical industry, including product liability claims and the availability of product liability insurance on reasonable terms; the difficulty of predicting the timing or outcome of future litigation or government investigations; periodic dependence on a small number of products for a material source of net sales; the variability of trade buying patterns; changes in generally accepted accounting principles; risks that the carrying values of assets and liabilities are impacted by future events and circumstances; the timing and success of product launches; costs and efforts to defend or enforce intellectual property rights; the availability and pricing of third party sourced products and materials; successful compliance with government regulations applicable to Allergan's and Pfizer's facilities, products and/or businesses; changes in the laws and regulations affecting, including changes in the pricing and reimbursement of pharmaceutical products; risks associated with tax liabilities, or changes in U.S. federal or international tax law or interpretations to which they are subject, including the risk that the Internal Revenue Service disagrees that Allergan is a foreign corporation for U.S. federal tax purposes; the loss of key senior management or scientific staff; and such other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2014, Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2015, Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015, and from time to time in Allergan's other investor communications. Except as required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.



Irish Takeover Rules and Non-GAAP Financial Information

5

Applicability of the Irish Takeover Rules

As the transaction constitutes a "reverse takeover transaction" for the purposes of the Irish Takeover Panel Act, 1997, Takeover no longer in an offer period and therefore Rule 8 of the Irish Takeover Rules does not apply to the transaction from the date of is no longer a requirement to make dealing disclosures pursuant to Rule 8.

Statement Required by the Irish Takeover Rules

The directors of Pfizer accept responsibility for the information contained in this communication other than that relating to Allergan and the directors of Allergan and members of their immediate families, related trusts and persons connected with them. To the best of their knowledge and belief (and to the best of their knowledge and belief they have taken all reasonable care to ensure that such is the case), the information contained in this communication for which they accept responsibility does not omit anything likely to affect the import of such information.

The directors of Allergan accept responsibility for the information contained in this communication relating to Allergan and the directors of Allergan and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the directors of Allergan (and to the best of their knowledge and belief they have taken all reasonable care to ensure that such is the case), the information contained in this communication for which they accept responsibility is in accordance with the facts and circumstances of the case and the information.

Goldman Sachs International, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority in the United Kingdom, and its affiliate, Goldman, Sachs & Co, are acting as joint financial adviser to Pfizer and no one else in connection with the proposed transaction, Goldman Sachs International and Goldman, Sachs & Co, their affiliates and their respective partners, directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to anyone other than Pfizer for providing the protections afforded to their clients or for giving advice in connection with the proposed transaction or any other matter referred to in this announcement.

Guggenheim Securities, LLC is a broker dealer registered with the United States Securities and Exchange Commission and is acting as financial adviser to Pfizer in connection with the proposed transaction. In connection with the proposed transaction, Guggenheim Securities, LLC, its affiliates, partners, directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to anyone other than Pfizer for providing the protections afforded to their clients or for giving advice in connection with the proposed transaction or any other matter referred to in this announcement. J.P. Morgan Limited (which conducts its UK investment banking business as J.P. Morgan Cazenove) ( J.P. Morgan ) is acting as financial adviser to Allergan and no one else in connection with the proposed transaction. J.P. Morgan Limited, its affiliates, partners, directors, officers, employees and agents will not regard any other person as its client in relation to the matters in this announcement and will not be responsible to anyone other than Allergan for providing the protections afforded to clients of J.P. Morgan or its affiliates, nor for providing advice in relation to any matter referred to herein.

Morgan Stanley & Co. LLC acting through its affiliate, Morgan Stanley & Co. International plc, is financial adviser to Allergan and no one else in connection with the proposed transaction. In connection with such matters, Morgan Stanley & Co. LLC, Morgan Stanley & Co. International plc, and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to anyone other than Allergan for providing the protections afforded to their clients or for providing advice in connection with the contents of this announcement or any other matter referred to herein. Unless otherwise defined, capitalised terms used in this Statement Required by the Irish Takeover Rules shall have the meaning given to them in the Statement Required by the Irish Takeover Rules issued by Pfizer and Allergan on November 23, 2015.

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE IT WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.**

#### Non-GAAP Financial Information

This presentation includes certain financial measures regarding Pfizer that were not prepared in accordance with U.S. generally accepted accounting principles. Non-U.S. GAAP financial measures presented should not be viewed as substitutes for financial measures required by U.S. GAAP. Such measures may not be comparable to the calculation of similar measures of other companies.



## Creating a New Global Biopharmaceutical Leader

6

### Best-in-Class Businesses

Bolsters top-tier innovative biopharma business with leadership positions in new therapeutic areas of growth

Creates

the

world's

leading

1

established

products business well-positioned for

global long-term growth

Enhances Growth Profile

Strengthens top-line growth potential

Deep pipeline of innovative therapies

Opportunity for meaningful synergies

Leverages experience of both

companies in integrating large

organizations

Increases Financial Flexibility

Substantially improves access to cash for

investment in bringing new medicines to

patients and direct return to shareholders

Increased flexibility better enables

continued investment in the U.S.

Preserves Future Optionality

Allergan strategically fits with existing

Pfizer Innovative and Established

structure

Improves growth durability and

financial flexibility of both businesses

1. Measured by revenue.



Innovative  
Established  
(Including Hospira)  
2013-2015

Build two pharma  
businesses with  
distinct capabilities

Pfizer has Been on a Consistent Path to Create  
Best-in-Class Innovative and Established Businesses

Trademarks are the property of their respective owners and used for information purposes only.  
2010-2013

Focus on core  
pharma business and  
unlock trapped value

Enhance Category Leadership  
7

Nutritionals  
Generate Sustainable Growth  
Optimize Capital Structure  
Leverage Global Scale  
and Capabilities

2015+  
Optimize our two pharma  
businesses while fully utilizing  
enterprise capital structure

Allergan Accelerates Pfizer's Strategic Objectives

8

Enhance Category Leadership

Generate Sustainable Growth

Optimize Capital Structure

Leverage Global Scale

and Capabilities

Strong innovative category leadership with durable flagship franchises built on exceptional customer connections  
Multiple drivers of innovative growth across a broad mix of payer types  
Potential revenue synergies driven by durable product franchises that can benefit from Pfizer's global scale for growth  
High degree of financial flexibility





A Strong Foundation From Which to Build

9

2015E  
Pro Forma  
Revenue

~\$48  
billion

1  
Powerful  
Global  
Capabilities  
and Reach

~30,000 U.S. colleagues

~65,000 ex-U.S. colleagues

Enhanced  
Innovative  
Category  
Leadership

~\$16  
billion

2

~10,000  
U.S.  
colleagues  
3

~5,000  
ex-U.S.  
colleagues  
3

Oncology

Vaccines

Cardio Metabolic

Rare Diseases

Inflammation &  
Immunology

Aesthetics & Dermatology

Eye Care

Neuroscience

1.

Represents mid-point of Pfizer 2015 revenue guidance range issued on October 27, 2015. Please see Pfizer's Current Report on Form 10-Q for the fiscal quarter ended September 27, 2015 for assumptions and disclosures regarding

2.

Based on Allergan's public disclosure dated July 27, 2015 for the remaining Allergan business pro forma for the pending divestiture of Allergan's generic business to Teva.

3.

Pro forma for the pending divestiture of Allergan's generic business to Teva.

Sustainable Growth  
Platform with  
Category Leadership  
Capabilities in

Maximizing

Established Brands

Allergan is a Growth Pharma Leader

10

Double digit branded sales

growth

1

Product line depth and category leadership

Productive investment in R&D through focus on

Open Science model

Highly-efficient SG&A spending

Experienced team committed

to success

Powerful global supply chain recognized as a

leader in customer service

Innovative Revenue

Growth

2

Double Digit

Established Revenue

Growth

2

Mid Single Digit

Source: EvaluatePharma and analyst consensus.

Note: Allergan figures are pro forma for the pending divestiture of Allergan's generic business to Teva.

1.

As disclosed in Allergan's Q3 2015 Earnings release dated November 4, 2015.

2.

Represents

anticipated

growth

for

2016E

2020E

based

on

analyst

estimates.

Characteristics that Define Our Exceptional Company

Allergan's World-Renowned Brands

11

Women's Health

Other

(including CV)

Anti-Infectives

Urology

Eye Care  
Aesthetics &  
Dermatology  
Neuroscience  
GI  
U.S. & Canada  
U.S. & Canada  
International  
International

More Than 70 Mid-to-Late Stage Development  
Opportunities in Key Therapeutic Areas

12

Skin Quattro Device

Delivery for  
Facial Fillers

21



Aesthetics &  
Dermatology  
Oxymetazoline  
Rosacea  
Aczone Reform  
Acne Vulgaris  
Sarecycline  
Acne  
Juvederm  
Global Nasal  
Labial Folds  
Vobella  
Lips Fine Lines  
Botox  
Forehead  
Lines  
Volift  
Nasolabial Folds  
Voluma  
Filler for Temple  
Voluma Plus  
Facial Volumes  
Voluma Global  
Malar Augmentation  
Phoenix  
Breast Augmentation  
VoLite  
Filler  
Voluma  
Filler for Chin  
Oxybutynin  
Hyperhidrosis  
Bimatoprost  
Androgenic  
Alopecia  
MT10109L  
Aesthetics  
Facial Lines  
HA Threads  
Forehead & Neck  
Aczone Combo  
Acne Vulgaris  
Setipiprant  
Androgenic Alopecia  
Bimatoprost  
Submental Fat  
Reduction  
Women s Health  
4  
Estradiol

Vaginal Cream VVA &  
Dyspareunia  
Ulipristal  
Fibroids  
Estradiol  
Vag Caps VVA  
& Dyspareunia  
Etonogestral Ring  
Contraception  
9  
CNS  
Rapastinel  
MDD  
AGN-241689  
Migraine  
Prophylaxis  
Ubrogepant  
Acute  
Migraine  
Botox  
MDD  
Vraylar  
Multiple  
Semprana  
Acute Migraine  
Vraylar  
Bipolar Depression  
Botox X  
Spasticity  
AGN-241660  
MDD  
9  
Biosimilar X  
Indication X  
Nebivolol/Valsartan  
Hypertension  
Botox  
Multiple  
Bevacizumab  
Multiple Cancer  
Cetuximab  
Multiple Cancer  
Trastuzumab  
Multiple Cancer  
Rituximab  
Non-Hodgkin  
Lymphoma  
TRV-027  
Acute Heart Failure  
Armour Thyroid

Hypothyroidism  
Other  
(Biosimilars, Cardiovascular and other)  
Urology  
4  
Botox  
Premature  
Ejaculation  
LiRIS  
Interstitial  
Cystitis  
SER-120  
Adult Nocturia  
Botox  
Indication X  
17  
Eye  
Care  
Tripligan  
(MMT) Ocular  
HTN & Glaucoma  
FPR2  
Agonist Dry Eye  
Disease  
Mimetogen  
Dry Eye  
Bimatoprost SR  
Glaucoma  
Ganfort  
MDPF  
Restasis  
MDPF  
Omega 3 OTC  
Dry Eye  
Pilo/Oxy  
Presbyopia  
Cortisol Analog  
Dry Eye Disease  
Brimo DDS  
Atrophic AMD  
Androgen  
Evaporative Dry Eye  
Cyclosporine SR  
Dry Eye  
DARPin  
®  
DME  
Dual DARPin  
®  
AMD

DARPin

®

SR

AMD

OCU Tearbud 1

Dry Eye

DARPin

®

AMD

GI

Linzezz

OIC

Linzezz

Colonic

Release CIC

Linzezz

Low Dose CIC

Viberzi

IBS-D

5

Relamorelin

Diabetic

Gastroparesis

Avycaz

cUTI, cIAI

5

Anti-Infective

Dalbavancin

Osteomyelitis

Dalbavancin

Endocarditis

Dalbavancin ABSSSI

Single Dose

Aztreonam /

Avibactam

Gram Neg Infect

Source: Allergan standalone pipeline information as of Allergan R&D Day on November 4, 2015.

Why Combination is Attractive for Allergan  
Stakeholders

13

Accelerates strategy to move up the value chain and creates a new  
leader in innovative biopharmaceuticals

Leverages long-term upside  
of enhanced combined innovative pipeline

Ability to leverage Pfizer's global scale  
to maximize value of Allergan's  
leading innovative franchises

Delivers immediate, long-term value to Allergan shareholders  
and

continued shareholder returns (including dividends, buybacks)

Opportunity to continue delivering significant shareholder value through  
enhanced scale, capabilities and operating synergies

Transaction Overview  
14  
Purchase  
Price  
Name and  
Relative  
Ownership

Shareholder  
Consideration

\$160B transaction, based on 11.3 shares of the combined company for each Allergan share, implying a price of \$363.63 per Allergan share<sup>1</sup>

Pfizer stockholders receive 1 share of the combined company for each Pfizer share, or may elect to receive cash for some or all of their Pfizer Inc. shares  
4

Allergan shareholders receive ~4.7B<sup>3</sup> shares of the combined company as a result of an 11.3-for-1 share split

Shares to remain NYSE listed and traded under the PFE ticker

Pfizer and Allergan will be combined under the existing Allergan entity and the continuing company will be called Pfizer plc<sup>2</sup>

Pfizer stockholders will own ~56% of the combined company shares<sup>3</sup>

1. Allergan price per share based on Pfizer closing share price of \$32.18 on November 20, 2015 and an assumed 11.3 for 1 split
2. Subject to shareholder vote.
3. Pro forma ownership is on a fully diluted basis assuming \$12 billion cash paid and does not consider ordinary course buybacks
4. Total cash paid in the merger will be a minimum of \$6 billion and a maximum of \$12 billion, and stock and cash elections will ensure that at least \$6 billion and no more than \$12 billion of cash is paid in the merger.



Transaction Overview

continued

15

The Combination is at an  
Implied Price of \$363.63 per Allergan  
Share<sup>1</sup>

Allergan increases amount of its authorized

share capital,  
and

Allergan effects an 11.3-for-1 share split and  
Allergan shareholders hold ~4.7B<sup>3</sup>  
shares of the  
combined company, which allows for  
Current Pfizer stockholders to receive ~5.9B<sup>3</sup>  
new  
shares of the combined company through a 1-for-1  
share exchange, with the ability to elect to receive  
cash in lieu of combined company shares

4

1.

Allergan price per share based on Pfizer closing share price of \$32.18 on November 20, 2015 and an assumed 11.3 for 1 split of

2.

Subject to shareholder vote.

3.

Pro forma ownership is on a fully diluted basis assuming \$12 billion cash paid and does not consider ordinary course buybacks

4.

Total cash paid in the merger will be a minimum of \$6 billion and a maximum of \$12 billion, and stock and cash elections will  
at least \$6 billion and no more than \$12 billion of cash is paid in the merger.

Using Existing Irish Allergan TopCo

~56%<sup>3</sup>

~44%<sup>3</sup>

Pfizer plc

Combined Company

Renamed Pfizer plc<sup>2</sup>

Pro Forma

Ownership

Pro Forma

Ownership

1

2

3

Transaction Overview  
continued  
16  
Location  
Governance  
Closing

Global operational headquarters in New York

Maintain Allergan's Irish domicile

Closing expected in the second half of 2016

Subject to customary closing conditions, including Pfizer and Allergan shareholder approvals and regulatory approvals, as well as completion of Allergan's pending divestiture to Teva

Both companies have the right to terminate in specified circumstances with termination fees of up to \$3.5 billion

Unanimously approved by both Boards

Pfizer plc's Board is expected to have 15 directors, consisting of all of Pfizer's 11 current directors and 4 current directors of Allergan, including Allergan's current Executive Chairman and Allergan's current CEO

Pfizer's Chairman and CEO will serve as Chairman and CEO of the combined company and Allergan's CEO will serve as President and COO

Financial Highlights

17

More than \$2B in expected peak annual operating synergies

Full synergies are projected to be achieved over the first 3 years post-close  
Synergy

## Capture

Significantly expands access to cash, providing optimal financial flexibility, including substantial continued investment in the U.S.

Expect combined operating cash flow in excess of \$25B beginning in 2018

Expected

pro

forma

adjusted

effective

tax

rate

to

be

approximately

17%

18% by the first full year after closing

Enhanced

Financial

Flexibility

Expected

to

be

neutral

to

adjusted

diluted

EPS<sup>1</sup>

in

2017,

modestly

accretive

beginning in calendar year 2018, more than 10% accretive in 2019 and

high-teens percentage accretion in 2020<sup>2</sup>

Compelling

Earnings

Accretion

Enhanced

Growth

Profile

Enhances top-

and bottom-line growth profile of both innovative and

established businesses

Remain committed to attractive current dividend policy, targeting a

50% dividend payout ratio

Strong  
Shareholder  
Returns

1. Adjusted income and its components and adjusted diluted EPS are defined as U.S. GAAP reported net income and its components excluding purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items.

2. Expectations include the impact of expected share repurchases following the transaction.

1

Vaccines  
Best-in-Class Innovative Business  
18  
Oncology  
Cardio  
Metabolic  
Rare Disease



Inflammation &

Immunology

Aesthetics &

Dermatology

Eye Care

Expands Innovative Category Leadership With Strong Flagship Products

Projected to Generate Sustainable Innovative Growth

Diversifies portfolio

of payer types

Strengthens capabilities in

developing and sourcing

new molecular entities and

new indications

Adds portfolio of growing,

durable flagship franchises

Selected

Brands

Note: Investing in neuroscience R&D to position Pfizer for a category leadership position in the longer-term.

Top-Tier Growth Pharma Business Positioned for  
Sustained Long-Term Leadership

19

2016E

2020E Consensus<sup>1</sup>

Innovative Business Revenue CAGR

Expected Innovative Business Growth

Sustained by Strong Pipeline

2

Over 100 innovative mid-to-late stage  
programs in clinical development

New Products

New Indications

High Single Digit

Mid Single Digit

1.

Represents anticipated growth for 2016E - 2020E based on analyst estimates.

2.

Represents combined pro forma Pfizer-Allergan innovative revenue. Assumes Pfizer's Lyrica and Viagra are moved to Establishments with Limited Ownership (peri-LOE) status.

Increased scale

Durable mature product franchises  
in key therapeutic areas including  
CV, neuroscience, pain, women's  
health and anti-infectives

Managing peri-LOE products in  
developed markets

Leveraging Pfizer's global scale to  
drive strong emerging markets  
growth across the portfolio

The World's Leading<sup>1</sup>

Established Products Business

20

Pro Forma Scale and Complementary Capabilities

Maximize the Combined Established Products Portfolio

Combined Scale

Combined Capabilities

Established

Product

2015E Pro Forma Revenue

>\$30

BILLION

Source: EvaluatePharma and analyst estimates.

Note: Assumes Pfizer's Lyrica and Viagra are moved to Established Business given peri-LOE status.

1. Measured by revenue.

Combined Proven Track Record of Successful Integration

21

Immediate focus on early integration planning

Will identify

best-of-the-best of both organizations

Complementary corporate cultures will enable colleagues to  
build upon mutual areas of expertise

Legacy businesses have a strong record of  
meeting and  
exceeding synergy targets  
Long History of Successful Integration  
of Transformational Business Combinations

Key Takeaways

22

Best-in-Class Businesses

Enhances Growth Profile

Preserves Future Optionality

Increases Financial Flexibility

A Compelling Combination